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Introduction
The major Histocompatibility Complex (MHC) is a 
group of genes located on short arm of Chromosome 
number six (6p21.3). In humans, the MHC gene 
products are called human leukocyte antigens 
(HLAs). This region contains 200 genes, many of 
which involve in immune responses. The genes 
encode the HLA Class I (A, B,C) and Class II (DR, 
DQ, DP) molecule (Figure1). The essential role of 
the HLA antigens is the initiation and regulation 
of the immune response(Table 1). 
The physiologic function of MHC 
molecules is the presentation of 
peptide antigen to T lymphocytes 
and distinguishes “self” from “non-
self. The clinical utility of HLA 
typing in following purposes:
1) Bone Marrow Transplantation
2) Solid organ Transplantation
3) Transfusion Medicine
4) Marker of Autoimmune diseases
Signifi cance of HLA Typing in Transplant 
Medicine 
From the Editor’s Desk
Nazneen Islam and Afsheen Ibrahim 
Molecular Pathology 
This issue’s goal is to impart transplant related 
information to health care providers in a readable, 
understandable format that will not become 
outdated anytime soon. Focusing on this, we have 
strived to compile topics that cover the spectrum 
of basic knowledge, important investigations, 
clinical conditions and newer techniques in the 
field of transplantation. Continuing the quest 
for knowledge while keeping the interest alive, 
this issue therefore contains broad variety of 
topics on Haemopoietic stem cell and kidney 
transplantation.
Transplant medicine is complex and 
multidisciplinary. Accordingly, the articles in this 
issue are on pretransplant evaluation, signifi cance of 
HLA typing, blood product utilization in transplant 
recipients, monitoring of immunosuppressive 
therapy and infections in neutropenic patients 
to name a few. This diversity of articles has 
been carefully created so that our readers fi nd it 
appealing and useful to the utmost level. 
Dr Natasha Ali 
Hematology  
Figure 1. The MHC locus on chromosome 6 covers about 4 Mb of DNA, 
depending on the individual. Class I genes are 3-6 kb long and class 
II genes are 4-11 kb in length. TNF-α and TNF-β are not part of the 
polymorphic HLA system.
Table 1. Description of MHC Class I& Class II locations and function
MHC Region
Class I 
Class II
Gene Products
HLA-A, HLA-B, 
HLA-C
HLA DR, HLA 
DQ, HLA DP 
Tissue Location 
All nucleated cells 
B lymphocytes,
monocytes,
macrophages, 
dendritic cells, 
activated T cells, 
activated endothelial 
cells, skin 
Function
Identifi cation and  
destruction of         
abnormal or infected 
cells by cytotoxic T 
cells
Identifi cation of 
foreign antigen by 
helper T cells
5) Population genetics of the HLA system
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HLA and Transplant Immunity
Histocompatibility molecules of one individual act as 
antigens when introduced into a different individual 
in organ transplantation. Mismatched HLA antigens 
can stimulate B cells to produce alloantibodies, 
which are involved with humoral mechanisms of 
transplant rejection,  Class I antigens controlled by 
the HLA-A, -B and -C loci are the primary targets of 
alloantibodies, studies also  indicates that antibody 
reactivity to class II antigens encoded by HLA-DR 
and HLA-DQ antigens may also result in graft loss. 
  Humoral Immunity
    Against Class I HLA antigens
    Complement-dependent antibodies
    Complement-independent antibodies
 Against Class II HLA antigens
  Cellular Immunity
 Direct allorecognition
 Cytotoxic CD8 T-cells
 Effector CD4 T-cells
 Regulatory T-cells
 Indirect allorecognition
 Effector CD4 T-cells
  HLA-Restricted Immune Responses
 Antiviral immunity
 Cytotoxic CD8 T-cells
 Recurrent autoimmune disease
 Effector CD4 T-cells
   Matching for HLA-A, -B, and -DR Antigens
   Mismatching for HLA-A, -B, and -DR antigens
    Broad vs split antigens
 Acceptable and unacceptable mismatches for highly  
    sensitized
    Candidates
    Permissible mismatches with graft outcome similar to  
    on-mismatched transplants
   DR Matching
   CREG Matching
    Public and private class I epitopes
   Structurally Based Matching
    Amino acid residue mismatching
    HLA Match maker
Abbreviations: HLA human leukocyte antigen; CREG  cross-reacting 
groups of antigens
Reference: American Society for Histocompatibility and Immunogenetics, 
2004
Clinical Reality of HLA Matching, Graft Survival 
and Outcome
HLA matching signifi cantly reduces the risk of 
graft rejection and graft failure after solid-organ 
transplantation and graft-versus-host disease (GvHD) 
after hematopoietic stem-cell transplantation.
For example in kidney transplantation, current 
criteria for HLA matching consider three loci: 
HLA-A, HLA-B and HLA-DR Many studies have 
shown the superior results with zero HLA-A, B, DR 
mismatches which expand longer allograft half-
lives (12.5 versus 8.6 years) and increased 10-year 
survival (52 versus 37 per cent). However in bone 
marrow and stem cells transplantation the donor’s 
and recipient’s HLA tissue types match plays a large 
part in survival. A match is better when all 5 of the 
known major HLA antigens are the same as fi ve out 
of fi ve match.
   Quality of Donor Kidney
    Donor age: expanded criteria donors
 Extended ischemia time
 Living donors
  Recipient Risk Factors
 Pediatric recipients
 Ethnicity
 Sensitization
 Immunosuppression
Molecular Analysis of HLA Typing
Various molecular methods have been evolved for 
HLA DNA typing. PCR SSP i.e. Sequence specifi c 
Primer based PCR is one of the reliable method 
because among them. PCR-SSP methodology is 
based on the principle that completely matched 
oligonucleotide primers i.e. HLA-A, B, C, DR and 
DQ alleles. Primer pairs are designed to be matched 
with single alleles or group(s) of alleles depending 
upon the degree of typing resolution required. 
Completely matched primer pairs allow amplifi cation 
to occur, i.e. a positive result, whereas mismatched 
primer pairs doesn’t allow amplifi cation to occur, i.e. 
a negative result (Figure 3). After the PCR process, 
the amplifi ed DNA fragments are size-separated 
e.g. by two per cent agarose gel electrophoresis, 
visualized by staining with ethidium bromide 
and exposure to ultraviolet light, documented by 
photography and interpreted. Interpretation of PCR-
SSP results is based on the presence or absence of 
specifi c PCR product(s) (Figure 4).
Table 2. Potential effects of human leukocyte antigen (HLA) 
on transplant immunity
Table 3. HLA matching protocols for kidney transplantation
Table 4. Confounding factors for Kidney Transplant
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Figure 4. Gel electrophoresis of HLA Typing SSP
Ref: Olerup, Micro SSP HLA-A, HLA-B, HLA-C plate
Figure 3.  Principle of PCR-SSP. Allele-specifi c product only from those wells containing primers matching the specimen HLA allele. Wells containing 
primers that do not match the patient’s HLA allele will have a band only from the internal control.
Result Interpretation:
 After Electrophoresis gel photograph are  
examined and positive lanes determine carefully 
 An internal positive control band, should be 
visible in all gel lanes, except in the negative 
control gel lane, as a control of successful 
amplifi cation. The internal positive control band 
may be weak or absent in positive gel lanes. 
Beta globin internal control
Positive Amplifi cation Band
Mismatched Matched 
DN
Internal controls
Allele-specifi c product
Amplifi cationNo Amplifi cation
A
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Renal transplantation has become the treatment of 
choice for patients with end-stage renal disease. 
Protocol biopsies early after transplantation have 
detected subclinical disease, which has excited 
clinical investigators and prompted them to consider 
this as a potential surrogate marker for evaluating 
transplantation outcome.
Types of Renal Allograft Biopsies
  Implantation biopsy (donor biopsy):   
  Individual zero time biopsies have been 
  shown to correlate with the graft outcome
  Indication biopsy: Dysfunctional allograft  
  biopsy and allograft biopsy for proteinuria
  Protocol biopsy
Protocol Renal Biopsy
It is performed at pre-determined intervals after 
transplantation in normal functioning allografts. 
Aided research and provided insights into the 
pathogenesis of early and late allograft injury.
Role in Clinical Practice
  Detection of subclinical rejection (SCR)
  Individualization of therapy in high-risk  
  patients and safe reduction of    
  immunosuppression in standard risk
  individuals becomes possible
  Chronic T cell or antibody-mediated   
  rejection
  Recurrent or de novo glomerulopathies
  Viral nephropathy
  Interstitial fi brosis/ Tubular atrophy(IF/TA)
  Chronic calcineurin inhibitor(CNI) -  
  nephrotoxicity, allowing modifi cations of  
  therapy to limit ongoing graft injury
When to Perform?
Optimum timing of surveillance biopsies depends 
on the pathology.  Biopsies up to three months from 
transplant show a higher frequency of SCR with a 
greater incidence of IF/TA beyond six months and 
presentation of recurrent and de novo GN, TG and 
CNI toxicity occurring at various time points from 
transplantation. Early surveillance biopsy yields 
the greatest reversible pathology while biopsies 
beyond one year serve as prognostic indicators of 
graft survival and help tailor immunosuppression 
according to the individual.
Preparation of the Biopsy for Evaluation
The biopsy should be processed and prepared 
according to the renal transplantation guidelines 
for allograft biopsy handling by an experienced 
technologists. Allograft biopsies are processed by the 
rapid method using auto processor and are reported 
on the same day. According to Banff scheme, it is 
recommended to prepare at least seven slides(3-4 
microns thick), with multiple sections mounted on 
each slide. Three of these should be stained with 
hematoxylin and eosin (H&E), three with periodic 
acid-Schiff reagent (PAS) and one with a Masson’s 
trichrome stain.
Pathological Evaluation 
The accurate pathologic evaluation of renal 
allograft biopsy requires a well-trained renal 
pathologist with a thorough knowledge of renal 
transplant pathology, and also of renal and 
transplant medicine in order to correlate the 
morphologic abnormalities with the detailed 
clinical information. The importance of 
correlation of morphological findings on the 
renal allograft biopsy with clinical data and a 
close interaction between the nephrologists and 
pathologists is no doubt of great significance.
Role of Protocol Renal Biopsies in Transplant 
Patients
Drs Sidra Arshad and Saroona Haroon
Histopathology
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Role of Special Stains and other Ancillary 
Studies
The PAS and/or silver stains are very useful 
in delineating tubular basement membranes 
(TBMs) and in defining the severity of tubulitis, 
and for evaluating glomerulitis. The PAS stain 
is also useful in the identification of arteriolar 
hyalinosis, tubular atrophy and their semi-
quantitative scoring. Trichrome stains help 
in assessing the chronic sclerosing changes 
in the interstitium and in the arterial intima. 
C4d antibody is performed to rule out humoral 
rejection process.
Future Recommendations 
While renal biopsy remains the current “gold 
standard “for investigation and assessment 
of allograft pathology, development of either 
supplementary molecular methods or minimally 
monitoring or noninvasive monitoring has 
to be expanded. The cost, risk and patient 
inconvenience of surveillance biopsies must 
be weighed against potential gains from early 
interventions guided by the findings. These 
biopsies have provided marked insights into the 
subclinical processes affecting the graft with 
implications for the long term graft outcome.
Umbilical Cord Stem Cells
Dr Natasha Ali 
Hematology 
In the developed world, haematological malignancies 
account for 10 percent of new cancer diagnosis. 
Many of these malignancies can be cured with 
chemotherapy alone. However, most of the time 
chemotherapy alone is not enough to achieve a 
cure and these patients then require haemopoietic 
stem cell transplantation (HSCT). HSCT provides 
curative therapy for a variety of diseases. Every 
year more than 30,000 patients with haematological 
malignancies receive high dose chemotherapy 
followed by HSCT. The stem cells used in the 
procedure can be obtained from bone marrow; 
G-CSF mobilized peripheral blood and cord blood. 
Despite this, the availability of a match related donor 
still remains to be limited. 
Umbilical cord blood availability as a prospect for 
therapeutic use was fi rst reported in Lancet in 1939. 
It was not until 1970s when the medical brothers 
Ende published the transplantation of multiple 
units of umbilical cord blood into an individual3. 
Although this procedure was not successful due 
to the multiple disparities of the transplant unit, 
it did pave a way to investigate cord blood on a 
more serious level. In 1988 eventually, successful 
transplant of a patient with Fanconi’s anaemia was 
performed and published in 19894. The possibility 
to use one of the largest cellular sources available, 
but normally discarded, was an exciting move which 
led to umbilical cord blood stem cells being used 
to treat a variety of malignant and non-malignant 
haematological disorders. Umbilical cord stem cells 
present a number of advantages over bone marrow 
stem cells (Table 1). 
Table 1. (Adapted from - The Journal of Perinatal Education, 
20(1), 54-60, doi: 10.1891/1058-1243.20.1.54)
Table 2: (Adapted from - The Journal of Perinatal Education, 
20(1), 54-60, doi: 10.1891/1058-1243.20.1.54)
Advantages of Umbilical Cord Blood Stem Cells 
Versus Bone Marrow Stem Cells
 Ease of collection
 No risk for mother or child
Less time needed for processing (more quickly available  
  for use)
Less costly than bone marrow collection
Less risk for transmission of infection
Less need for stringent antigen typing 
Less rejection
Disadvantages of Umbilical Cord Blood Stem Cells
Slow engraftment
Limited cell dose 
   Small volume of unit
   Additional cell doses unavailable
Autologous donation may have limited benefi t 
   owing to hereditary disorders
Storage issues
   Unknown length of long-term storage
   Cost related to long-term storage
   Quality control
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Blood Product Utilization in Haematopoietic 
Stem Cell Transplant Recipients
Dr Hira Qadir
Haematology
Introduction
Hematopoietic stem cell transplant (HSCT) 
patients often require intensive blood component 
support. Transfusion may be complicated by 
transfusion transmitted infection- both viral and 
bacterial, transfusion-associated (TA)-GvHD, 
febrile non-hemolytic transfusion reactions 
(FNHTR) and transfusion-related acute lung injury 
(TRALI). Alloimmunization to red cell antigens 
may cause diffi culties in selecting compatible 
blood while alloimmunization to the human 
leukocyte antigens (HLA) present on platelets may 
cause refractoriness to subsequent transfusions of 
randomly-selected platelets.
Leukodepleted Blood Components
Transfused leukocytes cause alloimmunization to 
HLA Class one antigens (HLA-A1) in a proportion 
of patients. This may be manifested clinically 
as FNHTRs, although these may also be caused 
by antibodies to neutrophils, platelets or plasma 
proteins and by cytokines such as interleukin 
(IL)-1, IL-6, IL-8 and tumor necrosis factor which 
accumulate in stored blood components, especially 
platelet concentrates. HLA-A1 may cause 
accelerated destruction of transfused platelets that 
are HLA incompatible. This is clinically manifest 
as a failure to achieve a satisfactory increment 
after platelet transfusion (refractoriness). Donor 
dendritic cells which are present in red cell and 
platelet transfusions appear to be responsible for 
sensitization to HLA. Studies show that removal 
of leukocytes to less than 5 x 106 per blood 
component prevents primary HLA-A1 in >97 per 
cent of patients with hematological malignancies. 
The use of leukodepleted components also reduces 
secondary A1 and refractoriness to platelet 
transfusion.
Indications for Leukodepleted Blood Components
  Pre-HSCT in patients with severe aplastic anemia  
 (SAA) to reduce the likelihood of graft failure
  Pre- and post-HSCT to prevent recurrent FNHTR
  Pre-and post-HSCT to minimize HLA-A1 and  
 platelet refractoriness
Many Blood Services have implemented 
leukodepletion of a large proportion or, in some 
cases, all of their blood components. In the UK 
universal leukodepletion was implemented in 1999 
with the aim of minimising the risk of transfusion 
However, like all therapies, it is associated with 
caveats (Table 2)
These stem cells are stored in stem cell banks 
after donation. There are three types of umbilical 
cord blood banks; private, public and direct-
donation banks. Private Banks are commercial 
that promulgate directly to expectant parents.  
Private Banks charge an initial fee for collection 
and processing and a yearly fee for storing the 
specimen. Public umbilical cord blood banks accept 
altruistic donations. Donated units are processed, 
antigen typed and stored for future use. Direct 
donation banks function as an amalgamation of 
public and private cord blood banks. They collect 
cord blood without charging fees. In addition, they 
accept autologous donations and reserve them only 
for the family. 
Umbilical cord blood, once thought of as a waste 
product of the birthing experience,  is now valued 
for its content of stem cells. Saving cord blood is 
a worthy undertaking for any family. Obstetricians 
and haematologists are one of the fi rst resources 
that an expectant family turns to for knowledge in 
order to reach an informed decision about collecting 
umbilical cord blood. Therefore, we as physicians 
should be well versed on the topic, so that as 
questions arise, the multiple facets of umbilical 
cord blood banking can be explored.
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associated transmission of the causative agent of 
variant Creutzfeld-Jakob disease (vCJD); As an 
alternative to CMV seronegative components.
Gamma-Irradiation of Blood Components and 
TA-GvHD
HLA incompatible third party leukocytes contained 
in donated blood components can engraft and 
initiate an alloreactive response after transfusion. 
This can cause TA-GvHD, manifest clinically by 
fever, rash, diarrhea, jaundice and pancytopenia, 
and this is fatal in >90 per cent of cases, so 
prevention is essential. Donor leukocytes are 
inactivated by gamma-irradiation of 2500 cGy 
and all components for HSCT recipients should be 
irradiated from the time that conditioning therapy 
is started and continued until six months post-
transplant or until the lymphocyte count is 1 x 
109/L in the absence of chronic GvHD. In addition, 
HLA matched packed red cells should be irradiated, 
as should those from family members.
Indications for Irradiated Blood Components
Allo-HSCT recipients from time of conditioning 
therapy for 6 months or until the lymphocyte
count is 1 x 109/L in the absence of cGvHD
  Auto-HSC recipients (from 7 days before harvest  
 until 3 months post transplant)
  All donations from HLA-matched donors or 1st or  
 2nd degree relatives
  All patients with Hodgkin disease at any stage of  
 therapy
  All patients treated with purine analogues e.g. 
 fl udarabine
  All patients with congenital immunodefi ciency  
 states
Red Cells
Red cells, are transfused to correct anemia due to 
marrow failure, hemorrhage or hemolysis, aiming to 
keep the hemoglobin or packed cell volume (PCV) 
above predefi ned levels to ensure good tissue 
oxygenation. Reduced intensity conditioning (RIC) 
transplants require fewer red cell transfusions. 
Red cells should be matched for ABO and Rhesus 
D type. Extended phenotyping may be necessary 
in patients, e.g. those who have formed red cell 
alloantibodies after previous transfusions. Red cells 
should be cross-matched against the patient’s serum 
by standard techniques prior to transfusion.
Platelet Transfusions 
Current practice, based on the results of 
randomized studies, is to transfuse platelet 
concentrates prophylactically when the platelet 
count is less than 10 x 109/L. A recent Cochrane 
Systematic Review concluded that, whilst there 
is no reason to change current practice, blood 
products may become scarcer and further trials 
should be undertaken to compare prophylactic 
versus therapeutic platelet transfusion.
Conclusion
Transfusion support in HSCT patients requires 
special consideration and carefully defined 
policies. The use of high quality blood 
components which have a high degree of 
microbiological safety, gamma-irradiated, may be 
CMV seronegative and leukodepleted provides 
optimum transfusion support and minimizes the 
chance of adverse effects.
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Dr Muhammad Ishaque and Dr Saroona Haroon
Histopathology
Use of Magic Marker “C4d” in the Diagnosis 
of Acute Antibody Mediated Rejection in 
Renal Transplant Patients
Renal transplantation is the treatment of choice for 
patients with end stage renal disease worldwide.  
Transplant rejection can be defi ned as an immune 
response of the patient that is activated against 
foreign material i.e. graft, which without treatment 
leads to the destruction of the graft. There are three 
different types of rejection when classifi ed according 
to the time of onset. 
1- Hyperacute or accelerated rejection usually   
 occurs during the fi rst hours after transplantation  
 and leads to the loss of the graft. In most cases it  
 can be avoided by the pre transplant cross match  
 test.
2- Acute rejection occurs usually during the fi rst 
 weeks or months after transplantation occurring  
 in 40 per cent to 70 per cent of the cases, if   
 mild rejections are included. It manifests  
 typically as asymptomatic elevation of serum  
 creatinine. The diagnosis is confi rmed by renal 
 graft biopsy which shows lymphocytic infi ltrate, 
 tubulitis and edema. Acute rejection usually 
 responds well to high dose corticosteroid   
 treatment.
3-  Chronic rejection is defi ned as a gradual but  
 progressive impairment of renal allograft 
 which can occur at any time after the initial post 
 transplantation months. It does not respond well 
 to antirejection treatment usually leading to the  
 loss of graft.
In recent years it has been recognized that about 
10% of acute rejection cases generally ensuing in 
the first three months, are due to donor specific 
antibodies, not detected before transplantation.   
In most of these cases antibodies are directed 
against class I or II HLA antigens, but sometimes 
they are directed towards different endothelial 
antigens and cannot be detected even with more 
advanced tests. 
That an antibody mediated process is operating in 
this type of rejection is testifi ed by the capillary 
deposition of C4d, which is a degradation product 
of the classic complement pathway. After an 
antigen-antibody complex fi xes complement, 
a cascade of events follows, with activation of 
several complement proteins. The complement 
protein C4 is split into C4a and C4b. C4b is then 
converted to C4d. A unique feature of C4d is that 
it binds covalently to the endothelial and collagen 
basement membranes, thereby avoiding removal and 
raising the possibility of serving as an immunologic 
footprint of complement activation and antibody 
activity. In 2003 ‘C4d’ was incorporated in the Banff 
classifi cation.
Together with the serologic evidence of 
circulating antibodies to donor HLA antigens or 
to other donor endothelial antigens that were not 
present at the pre-transplant cross-match, two 
cardinal morphologic features are needed for the 
diagnosis:
1)    Evidence of acute tissue injury such as:  
 (a)  acute tubular necrosis; 
 (b)  neutrophils and/or monocyte-macrophages  
  in peritubular and glomerular capillaries and/ 
  or capillary thrombosis or 
 (c)  fi brinoid necrosis/transmural infl ammation  
  of arteries
2)   Immunopathologic evidence of an antibody   
 action, such as: 
 (a)  C4d complement and/or immunoglobulins in  
  peritubular capillaries, or 
 (b)  immunoglobulin and complement in arteries  
  with transmural fi brinoid necrosis.
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If transplantation has occurred greater than one 
year from the time of the biopsy, the likelihood of 
recurrence of a native kidney disease is increased. 
For this reason, a full work-up like that seen for a 
native kidney biopsy is recommended. This includes 
light microscopic, immunofl uorescent, and electron 
microscopic analysis plus C4d. C4d by the indirect 
immunofl uorescence approach is a more sensitive 
than monoclonal antibody staining, it is performed 
on the frozen section tissue. 
C4d is detectable in the glomerular mesangium 
and at the vascular pole of the normal kidney. This 
emphasizes that there is constitutive turnover of 
immune complexes. When the burden of immune 
complexes increases with immune complex 
deposition diseases, C4d deposition overfl ows from 
the mesangium and vascular pole to the glomerular 
capillaries. In transplanted kidneys, Donor-
specifi c antibody (DSA) directly engages human 
leukocyte antigens (HLAs), which are present in the 
glomerulus as well as the peritubular capillaries. It is 
known that anti-complement protection in the PTCs 
is weaker than in the glomerulus (Figure 1).
Hence detection of the complement split 
product C4d in renal live related allograft biopsies is 
an important adjunctive tool to help understand the 
alloimmune response and, in particular, to diagnose 
antibody-mediated rejection (AMR). In patients with 
this form of rejection, renal insuffi ciency develops 
briskly but sometimes insidiously. Although a rescue 
treatment with new potent immunosuppressive 
agents and plasma exchange may be successful in 
some cases, the one year graft-loss ranges from 25 
per cent to 50 per cent. C4d is now one of the core 
diagnostic tools to identify AMR, and is being used 
in virtually all transplant centers around the world.
The diffi culties of interpreting focal staining patterns, 
the relatively low sensitivity of C4d as a marker 
for AMR in late renal allograft biopsies, and its 
lack of utility as a marker for antibody-mediated 
injury in biopsies of ABO-incompatible allografts 
suggest that C4d has lost some of its magic during 
the past decade. However, most experts come to an 
understanding that if complement targeted therapies 
will be part of our future treatment options; a marker 
such as C4d will still be obligatory to identify 
patients susceptible for those kinds of expensive 
treatments.
Figure 1. Donor specifi c antibodies engaging with human leukocyte antigen
Patient:
14 days after tx
rapid rise
in creatinine
Immuno-
fl uorescence
Immuno-
histochemistry
Consider 
positive
Consider 
negative
Consider 
positive when
performed by
immuno-
histochemistry
A defi nite diagnosis of acute antibody-
mediated rejection requires:
C4d deposition in peritubular
capillaries
Diffuse
(>50% ptc)
Focal (>10-
50% ptc)
or
Minimal or
absent
(0-10% ptc)
Presence of
donor-specifi c
antibodies
against:
  Donor-specifi c
 HLA molecules
  Blood group 
 antigen (ABO)
 isoagglutinins
  Endothelial cell
 antigens
Histological
features,
‘suspicious’ for
acute AMR:
Type 1: ATN-like
minimal infl ammation
Type 2: peritubular
capillaritis, glomerulitis,
or thrombosis
Type 3: arterial
fi brinoid necrosis
Source: Kidney Int  © 2012 Inernational Society of Nephrology
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Assessing Post Transplant Renal Function
Dr Lena Jafri
Chemical Pathology
Identifying kidney allograft dysfunction as soon 
as possible will permit timely diagnosis and 
management. Monitoring allograft function includes 
direct and indirect measurement of glomerular 
fi ltration rate (GFR) and quantitation of urinary 
protein excretion besides the invasive and various 
radiological tests available.  
Serum Creatinine
The standard test used to monitor graft function is 
serum creatinine measurement. Creatinine is derived 
from the metabolism of creatine in skeletal muscle 
and from dietary meat intake. It is released into the 
circulation at a relatively constant rate. Creatinine is 
freely fi ltered across the glomerulus and is neither 
reabsorbed nor metabolized by the kidney. However, 
approximately 10-40 per cent of urinary creatinine is 
derived from tubular secretion by the organic cation 
secretory pathways in the proximal tubule. Increased 
serum creatinine post-kidney transplant that is not 
explained by dehydration, urinary obstruction, high 
calcineurin inhibitor levels or other apparent causes 
is most likely due to an intragraft parenchymal 
process, such as acute rejection, chronic allograft 
injury, drug toxicity, recurrent or denovo kidney 
disease. 
Following is the diagnostic criteria for acute 
kidney injury:  an abrupt (within 48 hour) 
reduction in kidney function currently defined as 
an absolute increase in serum creatinine of ≥ 0.3 
mg/dL, a percentage increase in serum creatinine 
of ≥ 50 per cent (1.5-fold from baseline), or a 
reduction in urine output (documented oliguria 
of less than 0.5 mL/kg/hour for more than six 
hour). This criteria includes both an absolute and 
a percentage change in creatinine to accommodate 
variations related to age, gender and body mass 
index, and to reduce the need for a baseline 
creatinine but do require at least two creatinine 
values within 48 hour.
The serum creatinine concentration however is 
an indirect measurement of GFR. At low serum 
creatinine levels, small changes in creatinine can 
indicate large changes in function. It is  essential 
for clinical laboratories providing transplant 
service to keep a strict check on internal quality 
controls of serum creatinine and to keep its 
Table 1. Formulae for Estimating Glomerular Filtration Rate in adults.
Abbreviations: GFR= glomerular fi ltration rate; CrCl= creatinine clearance; Cr= creatinine; BSA= body surface area; MDRD= 
modifi cation of diet in renal disease; exp= exponential; CG= Cockcroft Gault.  Serum Cr in mg/dL, weight in kg, height in meters, 
age in years, and BSA in meter square.
Formulae
urinary Cr x volume x 1.73/ serum Cr x1440 x BSA
175 x  Cr (exp[-1.154])  x Age (exp[-0.203])  x  (0.742 if female)
(140 - age)  x weight / serum Cr [mg/dL] x 72 x  (0.85 for females)
If Cr < 0.9 (for male): 141 x (Cr/0:9)0. 411 x 0:993Age
If Cr > 0.9 (for male): 141 x (Cr/0:9) -1.209 x 0:993Age
If Cr < 0.7 (for female): 144 x (Cr/0.7)-0.329 x 0:993Age
If Cr > 0.7 (for female): 144 x (Cr/0:9)-1.209 x 0:993Age
Method of GFR calculation
CrCl 
(ml/min/1.73m2)
MDRD 
(mL/min/ 1.73 m2)
CG
(mL/min)
CKD-EPI
(mL/min)
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protein levels are below 500 mg/d. However, even 
these low levels are associated with reduced graft 
survival. The reason can be the native kidney or 
the allograft, probably as a consequence of the 
ischemia-reperfusion injury. Proteinuria falls after 
successful kidney transplantation within few weeks. 
The residual or late proteinuria represents graft 
injury.  Most allografts with proteinuria >1500 
mg/d have new glomerular pathology. Evidence on 
proteinuria after renal transplantation shows that 
microalbuminuria and more signifi cantly proteinuria 
after transplantation are markers of graft dysfunction, 
correlated both to graft failure and to cardiovascular 
risk indicators. In patients with proteinuria one has to 
exclude recurrent glomerulonephritis (refer to Table 
2) in order to avoid unnecessary immunosuppression. 
The 2009 Kidney Disease: Improving Global 
Outcomes (KDIGO) clinical practice guideline 
on the care of the kidney 
transplant recipient 
recommended to measure 
urine protein excretion at 
least once within the fi rst 
month after transplantation, 
every three months during 
the fi rst year and annually 
later on. For the new-onset 
proteinuria or unexplained 
nephrotic proteinuria renal 
allograft biopsy should 
be performed. Proteinuria 
and albuminuria can be 
quantifi ed with a 24 hour 
collection or by using spot 
urine collections (Albumin-
Creatinine Ratio (ACR) 
or Protein-Creatine Ratio (PCR)). KDIGO suggest 
that ACR and PCR are reasonable screening tests 
in the renal transplant recipients. The positive 
thresholds for proteinuria have been established 
to be >250 (men) or >355 (women) mg/g by ACR 
and >200 mg/g by PCR. The KDIGO guidelines 
recommend monitoring of proteinuria as part of 
routine transplant follow-up. Any positive screen 
should be confi rmed by a 24 hour urine collection. 
Twenty-four hour urine protein excretion is the gold 
standard for quantitative protein assessment. If the 
24 hour urine collection is problematic, the urinary 
protein/creatinine (mg/g) ratio assessed in‘spot’ 
urine is an excellent surrogate, as it has proved 
to have an excellent correlation with the protein 
content of a 24 hour urine collection. The KDIGO 
also suggest biopsy for unexplained proteinuria    
>3 g/day.
coefficient of variation within narrow limits 
(preferably with ±1SD). The clinical laboratories 
must use a creatinine method that has calibration 
traceable to an isotope dilution mass spectrometry 
(IDMS) reference measurement procedure. 
Additionally, patients with small muscle mass 
generate less creatinine on a daily basis and 
normal levels in such patients may mask allograft 
dysfunction in them. The increasing use of 
estimated GFR (eGFR) in clinical practice has 
renewed the interest on the shortcomings of serum 
creatinine alone.
Formulae that Estimate GFR
The most common methods utilized to estimate the 
GFR are: measurement of the creatinine clearance; 
and estimation equations based upon serum 
creatinine such as the Cockcroft-Gault equation, 
the Modifi cation of Diet in Renal Disease 
(MDRD) study equations, and the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) 
equation. However, none have not been validated 
in our population. Out of these equations which 
were developed for chronic kidney disease 
patients, the MDRD has been validated in renal 
transplant patients. 
Proteinuria
The rate of protein excretion in healthy adults 
is <150 mg/day, of which less than 30 mg is 
albumin while the rest comprises different 
proteins and glycoproteins originating from 
tubular epithelial cells. Proteinuria is common 
after kidney transplantation and typically urine 
Table 2. Causes of Proteinuria after Kidney Transplantation.
Allograft Rejection and Drug Toxicity
Acute rejection
Chronic allograft injury
De Novo and Recurrent Glomerular Disease
Minimal change disease
Focal segmental glomerulosclerosis
Membranoproliferative glomerulonephritis
Thrombotic thrombocytopenic purpura
Vasculitis
Light- and heavy-chain deposition disease
Diabetic nephropathy
Thrombotic microangiopath
Transplant glomerulopathy
IgA glomerulonephritis
Membranous glomerulonephritis
Postinfectious glomerulonephritis
Hemolytic Uremic Syndrome
Amyloidosis
Systemic lupus erythematosus
14
VOL. 40, ISSUE 2NOVEMBER 2014
Chronic renal failure impairs processes of 
hemostasis in complex ways. Accumulation of 
protein biodegradation products disturbs platelet 
production and function, resulting in a hemorrhagic 
diathesis. The bleeding tendency is increased by 
vascular defects and defi ciency of clotting factors 
II, V, IX, and X (Figure 1). On the other hand, high 
concentrations of fi brinogen as well as VII and XIII 
clotting factors in uremic patient plasma increase the risk 
of thrombosis. Thrombus formation is not controlled 
by clotting inhibitors, because of impaired activity of 
antithrombin III, heparin cofactor II, as well as proteins 
C and S. Additionally, injury to vascular endothelium 
stimulates production of factor VIII and von Willebrand 
factor. Finally, decreased plasma fi brinolytic activity is 
observed in uremic patients (Figure 2).
Coagulopathy in Renal Transplantation 
Dr Anila Rashid
Haematology
Successful kidney transplantation does not result 
in complete regression of hemostatic disturbances. 
There are several factors relevant in the peri- 
and post-transplant periods known to infl uence 
the coagulation process, such as the function 
of the kidney, the immune response, and the 
immunosuppressive agents used post-transplantation.
Bleeding is the most common early complication 
after transplant (6.1per cent-8.3 per cent). It concerns 
mainly platelet function and clotting inhibitor 
activities.
A hematoma in the kidney graft area is usually 
caused by bleeding from tiny vessels in the renal 
hilus that are constricted during the operation, and 
begin to bleed after improved graft perfusion. The 
Figure 1. Factors involved in increased risk of bleeding in patients with renal failure and transplant.
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origin of the bleeding can be bladder wall vessels; 
vascular anastomosis leaks; kidney graft rupture; 
or a spurious aneurysm due to an infected arterial 
anastomosis. The risk of bleeding is increased 
by perioperative antithrombotic and antiplatelet 
treatment. Hemorrhagic complications requiring 
surgical intervention signifi cantly increase the risk of 
transplanted kidney loss. 
Arterial thrombosis develops in 0.5 per cent to 3 per 
cent of transplanted kidneys. Renal vein thrombosis 
is observed in 0.5 per cent to 4per cent patients.
The reason for thrombosis in the early postoperative 
period is usually a technical failure: torsion 
or kinking of the vessel, an overly too narrow 
anastomosis, or injury to the endothelium. 
Other reasons can be cardiac arrest, persistent 
hypotension, acute rejection, diabetes mellitus, 
thrombophilia, and later, glomerulonephritis, post-
transplant erythrocytosis or the side effects of an 
immunosuppressive drug, particularly cyclosporine. 
Since the transplanted kidney does not possess a 
collateral circulation, arterial or venous thrombosis 
usually results in graft loss despite immediate 
surgical intervention.
Routine hematologic assessment of all transplant 
candidates includes a complete blood count, 
measurement of partial thromboplastin time, 
prothrombin time, International Normalized Ratio 
(INR), fi brinogen and D-dimer concentration. 
Patients with recurrent miscarriage, arterial/venous 
thrombosis, hemodialysis graft or fi stula thrombosis, 
or prior unexplained graft thrombosis should be 
evaluated for underlying hypercoagulable state like 
lupus anticoagulant, acquired inhibitors, inherited 
thrombophilia and may require anticoagulation therapy 
in the perioperative period. Patients with bleeding 
tendencies should have additional coagulation studies 
like bleeding time and platelet function test. 
Transplant physician along with hematologist should 
search for the risk factors both in pre- and post-
transplant period in order to detect high risk patients 
and apply suitable prophylactic measures.
Figure 2. Factors involved in increased risk of thrombosis in patients with renal failure and transplant.
Source: Lutz J et al. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014 Jan;29(1):29-40.
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concentration may be inappropriately elevated for 
given haemoglobin. 
Diagnostic evaluation includes the exclusion of 
renovascular hypertension or underlying malignancy 
and, in selected patients, an evaluation for chronic 
obstructive pulmonary disease (COPD). 
The preferred initial treatment for patients with 
PTE who have a hemoglobin concentration <18.5 
g/dL is an angiotensin receptor blocker (ARB) or 
angiotensin converting enzyme (ACE) inhibitor, 
since these agents are effective in the majority of 
patients, are reasonably safe, and, among many 
patients, provide a necessary antihypertensive effect.
Theophylline may be effective in some patients who 
cannot take ACE inhibitors or ARBs and for whom 
repeated phlebotomy is unacceptable. Alteration 
of the immunosuppressive regimen to include 
antiproliferative agents may be effective in treating 
PTE but is rarely done in the absence of other 
indications. 
For patients who present with hemoglobin >18.5 g/dL, 
therapeutic phlebotomy is recommended in addition 
to an ARB or ACE inhibitor. For patients who do 
not respond to ARBs or ACE inhibitors, intermittent 
phlebotomy is suggested rather than other therapies.
Post-transplant erythrocytosis (PTE) is defi ned as 
persistently elevated hemoglobin and hematocrit 
levels that occur following renal transplantation and 
persist for more than six months in the absence of 
thrombocytosis, leukocytosis, or another potential 
cause of erythrocytosis.
The threshold hematocrit used to defi ne PTE is 
variable and ranges between 51 to 54 per cent; 
most clinicians use 51 per cent (corresponding to a 
hemoglobin concentration of approximately 17 g/dL). 
The following hormonal systems and growth factors 
have been implicated in the pathogenesis of PTE:
  Erythropoietin
  Hematopoietic growth factors such as   
  insulin-like growth factor-1 and its binding 
  proteins and serum-soluble stem cell factor
  Renin-angiotensin system 
  Endogenous androgens
Even among PTE patients with serum erythropoietin 
concentrations within normal range, the 
Post Renal Transplant Erythrocytosis
Dr Maria Shafi q
Haematology
Therapeutic Drug Monitoring of Cyclosporine
Dr Sibtain Ahmed
Chemical Pathology
Cyclosporine is acyclic peptide composed 
of 11aminoacids. Discovered in the lab of 
Sandoz in Switzerland in 1972, cyclosporine 
has since revolutionized transplant medicine. 
It is a selective immunosuppressant agent. 
In the cytoplasm, cyclosporine binds to its 
immunophilin, cyclophylin forming a complex. 
The cyclosporine-cyclophylin complex binds 
and blocks the function of the enzyme a 
calcineurin, which has a serine/threonine 
phosphatase activity. As a result, calcineurin 
fails to dephosphorylate the cytoplasmic 
component of the nuclear factor of activated T 
cells, and thereby the transport of activated T 
cells to the nucleus. Consequently, T cells do 
not produce IL-2, which is necessary for full 
T-cell activation. Therefore it inhibits T cell 
activation.
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Cyclosporine is indicated for the prophylaxis of 
organ rejection in kidney, liver, heart and bone 
marrow transplants. The drug may also be used in the 
treatment of chronic rejection in patients previously 
treated with other immunosuppressive agents. 
It is also used for the treatment of autoimmune 
conditions, such as rheumatoid arthritis and psoriasis 
to ease symptoms. Cyclosporine presents some 
pharmacokinetic features listed below that make 
therapeutic drug monitoring imperative:
  Narrow therapeutic index
  Extremely high pharmacokinetic variability
  Differences in bioavailability between   
  different pharmaceutical products on the 
  market
  High risk of interactions cytochrome P450 
  3A4 and 3A5 dependent with direct and 
  immediate consequences (over/under dosing)
  Nephrotoxicity that is dose dependent
The drug exhibits very poor solubility in water, and, 
as a consequence, suspension and emulsion forms of 
the drug have been developed for oral administration 
and for injection. Cyclosporine formulations are not 
bioequivalent and cannot be used interchangeably. 
Formulations are described as modifi ed (Neoral) 
and non-modifi ed forms (Sandimune). Peak 
concentrations are reached in two - six hours 
after oral administration with non-modifi ed 
formulations and 1 to 2 hours after the modifi ed 
forms. Elimination of cyclosporine is biphasic and 
is primarily biliary. Terminal half-life is variable 
with formulation and patient, ranging from fi ve to 18 
hours for the modifi ed forms and from 10 to 27 hours 
for the non-modifi ed forms.
Patients treated with the cyclosporine are at 
high risk of developing renal injury. Calcineurin 
inhibitor nephrotoxicity is manifested either as 
acute azotemia, which is largely reversible after 
reducing the dose, or as chronic progressive 
renal disease, which is usually irreversible. Other 
renal effects of cyclosporine include tubular 
dysfunction and, rarely, a hemolytic uremic 
syndrome that can lead to acute graft loss. 
Metabolic abnormalities resulting from alterations 
in tubular function noted with cyclosporine therapy 
include hyperkalemia, hyperuricemia, metabolic 
acidosis, hypophosphatemia, hypomagnesemia, and 
hypercalciuria. Acute cyclosporine nephrotoxicity is 
usually reversible with cessation of therapy as both 
the plasma creatinine concentration and systemic 
blood pressure fall toward baseline values for 
that patient . The important clinical problem is to 
differentiate cyclosporine-induced renal dysfunction 
from acute rejection. The only defi nitive diagnostic 
test is biopsy of the renal allograft.
Monitoring should take into account the blood 
level of cyclosporine and the therapeutic interval 
(different for renal, liver and heart transplantation) 
and the correlation that exists between this 
interval and acute graft rejection, on one hand, 
and nephrotoxicity, on the other hand.With eighty 
percent of cyclosporine sequestered in erythrocytes, 
whole blood is the preferred specimen for analysis.
Peak concentrations (C2) are defi ned as samples 
collected two hours post-dose. High levels of 
cyclosporine in peak samples are correlated with 
reduced rejection rates, especially in the fi rst year 
after transplant surgery.Therapeutic ranges usually 
are based on specimens drawn at trough or C0 
(i.e. immediately before the next scheduled dose).
Recommended therapeutic ranges for cyclosporine 
for various transplants are described in Table 1 and 
Table 2.
Table 1. Recommended Therapeutic ranges for Cyclosporine (C0 levels)
Post Renal Transplant
Up to 2 months
3 months 
4 - 12  months     
Post Liver Transplant  
Less than or equal to 1 month
2-6 months
        
More than 6 months 
Cyclosporine Levels
200-300 ng/ml
200 ng/ml
80-180 ng/ml
Cyclosporine Levels
350-450 ng/ml
250-350 ng/ml
170-240 ng/ml
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 Post Cardiac Transplant
Less than 6 weeks  
6-12 weeks   
More than 12 weeks    
Cyclosporine Levels
300-420 ng/ml
180-300 ng/ml
120-180 ng/ml
Post Renal Transplant
Up to 1 month 
2 months   
3-4 months 
5-6 months  
7-12 months     
Cyclosporine Levels
1700 ng/ml *
1500 ng/ml *
1200 ng/ml *
1000 ng/ml *
800 ng/ml *
Table 2. Recommended Therapeutic ranges for Cyclosporine (C2 levels)
* (+/- 20%)
The purpose of monitoring is to prevent rejection 
(graft survival) and improved tolerance (avoidance 
of adverse reactions, particularly nephrotoxicity 
and too high immuno-suppression). Trough (C0) 
residual concentration is directly correlated with 
nephrotoxicity, but it is not a useful marker for 
prediction of acute rejection. Both nephrotoxicity 
and acute rejection are better correlated with the 
area under the concentration-time curve measured 
between 0 - 4 hour or 0 -12 hour (AUC0-4, AUC0-
12). These values can be better estimated using the 
value of C2  than the residual concentration (C0).
Tacrolimus for Prevention of Transplant Rejection
Dr Shabnam Dildar
Chemical Pathology
Tacrolimus (previously known as FK506) is 
a 23-membered macrolide lactone antibiotic 
isolated from the fermentation broth of a 
fungus Streptomyces tsukubaensis. It is an 
immunosuppressive agent belonging to the 
calcineurin inhibitor group. It  emerged as a 
valuable therapeutic alternative to    
cyclosporine following solid organ 
transplantation, was granted approval by the 
U.S. Food and Drug Administration (FDA) for 
preventing rejection after liver (1994), kidney 
(1997), and heart transplants (2006). It is also 
used for the therapy of autoimmune diseases   
and to reduce inflammation in inflammatory 
bowel disease, severe steroid-refractory or 
steroid-dependent ulcerative colitis, and 
Crohn’s disease.
Mechanism of Action
After entry into the cell, tacrolimus binds to 
the FK-binding protein (FKBP) which is an 
intracellular cytoplasmic immunophilin. The 
drug-immunophilin complex binds and inhibits 
the activity of the phosphatase activity of 
calcineurin. The calcium/calmodulin-dependent 
protein phosphatase interrupts the calcium-
dependent signal transduction pathway in 
T-cells. Inhibition of calcineurin by tacrolimus 
leads to interference with translocation to the 
nucleus of various nuclear factors involved 
in the transcription of cytokine genes, such 
as the cytosolic subunit of the nuclear factor 
of activated T-cells. Thus preventing its 
entrance into the nucleus. Therefore leads to 
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the inhibition of T-cell activation, resulting in 
immunosuppression.  Although this activity is 
similar to that of cyclosporin, studies have shown 
that the incidence of acute rejection is reduced by 
tacrolimus use over cyclosporin. Although short-
term immunosuppression concerning patient and 
graft survival is found to be similar between the 
two drugs, tacrolimus results in a more favorable 
lipid profile, and this may have important long-
term implications given the prognostic influence 
of rejection on graft survival.
Tacrolimus Metabolism
Tacrolimus is highly lipophilic and is excreted 
from the body after receiving extensive 
metabolism. Tacrolimus is metabolized by 
Cytochrome P450 3A4 (CYP3A4), thus its 
concentrations are affected by drugs that inhibit 
(calcium channel blockers, antifungal agents, 
some antibiotics, grapefruit juice) or induce 
(anticonvulsants, rifampin) this enzyme. Target 
steady-state concentrations vary depending 
on clinical protocol, the presence or risk of 
rejection, time from transplant, type of allograft, 
concomitant immunosuppression, and side effects 
(mainly nephrotoxicity). Optimal trough blood 
concentrations are generally between 5.0 and 
20.0 ng/mL. Adverse reactions tend to occur 
the most frequently in the first few months after 
transplantation and decrease with time possibly in 
line with reductions in its concentration. Adverse 
reactions include nephrotoxicity, neurotoxicity, 
diabetogenesis, gastrointestinal disturbances, 
hypertension, infections and malignant 
complications.
Therapeutic Drug Monitoring of Tacrolimus
Tacrolimus has a low therapeutic index with a high 
inter-and intra-pharmacokinetic variability, and 
possesses several side effects and drug interactions. 
All these factors requires individualized monitoring 
of the drug levels in blood. Therapeutic monitoring 
of tacrolimus is useful for guiding dosage 
adjustments to achieve optimal immunosuppression 
while minimizing dose-dependent toxicity. 
Therapeutic drug monitoring of tacrolimus is usually 
initiated on the second or third day of therapy. It is 
continued for the fi rst two weeks, three - seven times 
per week; with a gradual reduction in the monitoring 
frequency. Therapeutic Drug Monitoring of 
tacrolimus is important for monitoring whole blood 
tacrolimus concentration during therapy, particularly 
in individuals who are on CYP3A4 substrates, 
inhibitors, or inducers. Is also essential to monitor 
tacrolimus levels when adjusting dose to optimize 
immunosuppression while minimizing toxicity and 
also for evaluating patient compliance.
Some key points to note while monitoring tacrolimus 
are:
Peak tacrolimus levels in whole blood are     
 achieved about one - two hours following oral   
 administration
The cornerstone of tacrolimus evaluation is the 
 trough level obtained 12 hours after the 
 administration of the drug. This measurement 
 provides a good indication of the total drug    
 exposure.
There is not a good correlation, as with some    
 other medications, between the dose of tacrolimus 
 given and level of drug in the blood
Absorption and metabolism of oral doses of 
 tacrolimus can vary greatly between people and 
 even in the same person depending on the time of 
 the dose and what, if any, food has been eaten
Tacrolimus can cause kidney damage 
 (nephrotoxicity), especially in high doses.     
 Measuring levels in patients who have had a 
 kidney transplant may help to distinguish between 
 kidney damage due to rejection (because drug 
 level is low) and kidney damage due to tacrolimus 
 toxicity (drug level is high)
Specimen Type and Therapeutic Range
Since 90 per cent of tacrolimus is in the cellular 
components of blood, especially erythrocytes, whole 
blood is the preferred specimen for analysis of 
trough concentrations. 
Target range for trough whole-blood sample is 
5-20 ng/ml. The recommended therapeutic range 
applies to trough specimens drawn just before the 
next dose (i.e. immediately before a scheduled 
dose). Blood drawn at other times will yield higher 
results. Higher levels are often sought immediately 
after transplant, but as organ function stabilizes at 
about 4 weeks from transplant, doses are generally 
reduced in stable patients for most solid organ 
transplants. Trough concentrations should be 
maintained below 20 ng/mL. Preferred therapeutic 
ranges may vary by transplant type, protocol, and 
co-medications.
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An Approach to Diagnosis of Infections in 
Febrile Neutropenic Patients
Dr Faryal Saleem
Microbiology
Febrile neutropenia is defi ned as ‘single oral 
temperature of 38.5°C or more or a temperature 
of 38°C recorded on three different occasions 
within a 24 hour period at least four hours apart 
in a neutropenic patient’. Here, neutropenia 
maybe defi ned as an absolute neutrophil count 
(polymorphnuclear cells) of 500/ml or less.
In as many as 50 per cent of the cases, infections are 
the main cause of febrile neutropenia. The infections 
maybe bacterial, fungal or viral in origin but many a 
times typical signs and symptoms of these infections 
are absent due to the altered host immune responses. 
Fever might be the only manifestation thus it is 
important for physicians to do stringent monitoring 
of patients especially when they are undergoing a 
neutropenic phase during their chemotherapy.
It is imperative that all measures are taken to 
diagnose and treat any infections that may be a 
cause of febrile neutropenia in patients. Antibiotic 
therapy must be started within one hour of the patient 
reaching the hospital. Apart from complete blood 
count, including differential leukocyte counts and 
other biochemical markers of infections, there are 
various tests that are used in a laboratory to diagnose 
infections, with blood cultures being the primary 
diagnostic modality. For blood cultures to yield 
valuable results it is important that they are taken 
with standard protocol of aseptic techniques. At 
least two  sets of blood cultures from two separate 
venipuncture sites are recommended. If indicated, 
cultures from any other clinically suspicious site may 
also be taken. Table 1 shows common organisms 
which are isolated from different clinical specimens 
through routine culture and molecular methods.
Positive blood cultures are gram stained and 
preliminary information is conveyed to the clinician 
so that any modifi cation in empirical therapy 
Table 1. Common Organisms isolated in various specimen cultures of Febrile Neutropenia
Causative Agent
Bacteria
Fungi
Viral
Organisms
Staphylococcus aureus
Streptococci
Pseudomonas species
Enterococci
Escherichia coli
Klebsiella species
Mycobacterium species
Candida species
Mucormycosis
Aspergillus spp
Cytomegalovirus
Herpes simplex virus
Specimens
Blood, pus, body fl uids, swabs from 
wounds etc.
Blood, urine, pus, body fl uids, 
swabs from wounds etc.
Sputum, bronchoalveolar lavage  
fl uid, pus etc.
Blood, urine, body fl uids, tissue 
culture etc.
Tissue culture, skin scrapings, etc.
Tissue culture, skin scrapings, etc.
Bronchoalveolar lavage fl uid, 
vesicular/pustular fl uid etc.
Diagnostic Modalities
Culture and sensitivities
Culture and sensitivities
Culture and sensitivities
Gram staining, culture and 
sensitivities, PCR
Gram staining, fungal smear and 
culture and sensitivities, 
PCR
fungal smear and culture and 
sensitivities, PCR
PCR
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may be instituted. Several rapid diagnostics and 
susceptibility methods have been developed from 
positive blood culture vials. Direct disc diffusion 
from positive vials is currently in use in several 
laboratories including ours. Molecular identifi cation 
using multiplex PCR, matrix assisted laser desorption 
ionization- time of fl ight (MALDI-TOF), fl uorescent 
in-situ hybridization (FISH) are just a few examples 
of advancements in rapid identifi cation techniques 
which are expected to improve patient management. 
Similarly susceptibility testing methods employing 
detection of resistance associated gene mutations 
can provide additional benefi t in guiding empirical 
therapy. 
Thus, it is essential for the clinicians to evaluate the 
patients suffering from febrile neutropenia carefully 
and send all the relevant investigations without any 
delay to fi nd out the etiology of fever as quickly as 
possible. In most of the cases a positive blood culture 
with proper identifi cation and susceptibility profi le of the 
causative agent is enough to warrant an early diagnosis 
of infection. In these cases, timely use of appropriate 
antimicrobials may prove to be lifesaving for the patient.
Signifi cance of CMV Antigenemia Assay In 
Renal Transplant Patients
Waqas Khan and Saher Faisal
Molecular Pathology 
Introduction
Pp65 CMV antigenemia test allows the indirect 
immunofl uorescence detection of internal matrix 
phosphoprotein (protein kinase) 65-68 KD (pp65) 
of Human Cytomegalovirus (HCMV) in peripheral 
blood leukocytes. The pp65 detection in peripheral 
blood leukocytes allows the diagnosis of acute or 
reactivated infection. The HCMV pp65 antigenemia 
is a rapid, quantitative, simple, sensitive easy for 
the diagnostic of active Cytomegalovirus infection. 
Antigenemia is more sensitive than viral isolation 
and rapid culture serology. In all cases, the sensitivity 
is 100% in symptomatic patients. Antigenemia can 
be detected from several days to one week before the 
onset of symptoms. Antigenemia is successfully used 
in the diagnostic and follow-up of HCMV infections 
in heart, heart-lung liver, kidney, and bone-marrow 
graft recipients and in AIDS patients.
Principle of the Assay
This method uses a monoclonal antibodies pool 
which recognizes  two epitopes of the protein (pp65)   
expressed in the nucleus of peripheral blood HCMV 
infected polymorph nuclear and mononuclear 
cells, during blood dissemination. Fluorescein 
isothiocyanate (FITC) conjugated antibody will bind 
to the antigen-antibody complex. Unbound conjugate 
is removed by washing with PBS. FITC exhibits an 
apple green fl uorescence when excited by ultraviolet 
light allowing visualization of the complex by 
fl uorescence microscopy. Nuclear fl uorescence 
indicates a positive specimen. Uninfected cells 
counter-stain dull red due to the presence of Evans 
blue in the FITC conjugated antibody reagent. 
Utility of the Assay
HCMV antigenemia test is recommended for 
the diagnosis of patients infected with CMV 
virus as  this test is used to detect the antigen of 
cytomegalovirus (CMV). This test may also be used 
when a  CMV infection is suspected in patients with 
HIV or organ transplant recipients. 
Results Interpretation
The HCMV isolation from leukocytes of peripheral 
blood (viremia) and/or pp65 antigenemia are 
Figure 1. Antigenemia Signal from a CMV Positive Patient
Source: virology-online.com/viruses/CMV4.htm
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evidence for active systemic infection. A single 
stained cell indicates a positive antigenemia.
Conclusion
Antigenemia is more sensitive than viral isolation, 
rapid culture and serology. Antigenemia can be 
detected from several days to one week before the 
onset of symptoms, and from two to 25 days before 
rapid culture.  Antigenemia is also positive for a 
longer period than viremia demonstrated by co-culture.
This test can be even performed by laboratories where 
the culture are not available, and only requires as 
specifi c apparatus a simple cytocentrifuge.
Pretransplant Serological Evaluation
Dr Hafsa Majid
Chemical Pathology
The success of solid organ transplantation requires 
careful selection of transplant recipient through a 
process of medical evaluation and screening. Two 
major complications occurring due to long term 
immunosuppression after transplant are infections 
and malignancy. That is why screening a potential 
transplant recipient for infectious diseases is an 
important pre-transplant component. Such screening 
may lead to the discovery and treatment of occult 
active infection improving patient outcomes, 
may help determine post-transplant prophylactic 
strategies, or may disqualify the recipient from 
receiving a transplant.
At the time a patient is identifi ed as a potential 
transplant recipient, an initial evaluation including 
a detailed history and physical examination is 
required to assess the candidate’s suitability for 
transplantation. This assessment includes laboratory 
screening tests and serological evaluation (Table 
1) to establish the candidate’s prior exposure to 
common organisms that may reactivate after organ 
transplantation . The United Network for Organ 
Sharing (USA) has issued this list of required 
infectious disease screening tests for both organ 
donors and potential recipients. Once a patient has 
cleared the initial evaluation, they may be listed for 
solid organ transplant.
Recommended hepatitis B (HBV) screening tests 
include hepatitis B surface antigen (HBsAg) and 
antibody (HBsAb) and hepatitis B core antibody 
(HBcAb). HBsAg positive or patients with any 
evidence of prior hepatitis B infection (HBsAg 
negative and HBcAb positive) can be further 
assessed by HBV DNA and treated if appropriate. 
Even patients with no evidence of viremia and 
isolated HBcAb positivity may experience HBV 
reactivation post-transplant occasionally leading to 
fulminant hepatitis. Patients with isolated HBsAb 
and a history of prior vaccination have demonstrated 
immunity to infection with hepatitis B and do not 
require HBV immunization pre-transplant. Screening 
for the presence of antibody to hepatitis C virus 
(HCV) in all candidates 
is necessary and further 
testing with HBV RNA if 
positive. Transplantation 
of non-hepatic organs 
into an HCV seropositive 
recipient may result in 
accelerated hepatitis and 
liver failure. Screening 
for viral pathogens such 
as HIV is a required part 
of the pre-transplant 
evaluation. Though not an 
absolute contraindication 
to transplant, HIV 
Pre-Transplant Serology Includes
Hepatitis B serology (HBsAg, HBcAb, HBsAb)
Hepatitis C Ab
HIV serology
CMV serology (IgM and IgG)
EBV serology
Toxoplasma IgG 
Interferon gamma release assay or PPD skin test for Mycobacterium tuberculosis 
Rapid plasma reagin (RPR) or specifi c treponemal testing
Table 1. Pre-Transplant Serology Recommended for All Potential Organ Recipients and Donors
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infection must be documented and viral replication 
controlled prior to surgery. 
Screening for cytomegalovirus (CMV), a common 
post-transplant infection is also recommended as it 
is potentially transmissible through transplantation 
and carry a predictable disease risk. The seronegative 
recipient for CMV Ab receiving a seropositive 
donor’s organ has the greatest risk of disease. 
Post-transplant cytomegalovirus may occur in any 
recipient positive (R+) case as well as in recipient 
negative patients exposed to the virus through 
blood transfusion or other close contact. Epstein-
Barr virus (EBV) infection is a risk factor for post-
transplant lymphoproliferative disease, particularly 
in seronegative patients who develop primary EBV 
infection due to seropositive donor. Screening for 
EBV can be done by testing Epstein Barr Nuclear 
Antigen (EBNA) IgG, EBV-Viral Capsid Antigen 
(VCA) IgM and EBV-VCA IgG. Primary infection 
is indicated by positive EBV-VCA IgM, EBV-VCA 
IgG and negative EBNA IgG. While past infection is 
presence of positive EBNA IgG, EBV-VCA-IgG and 
negative EBV-VCA IgM.
Although antibiotics given pretransplant provide 
coverage for infection with Toxoplasma, but 
screening for exposure to the parasite, Toxoplasma 
gondii is routinely performed. Because the organism 
can form cysts in organs especially myocardial 
tissue, so seronegative recipients of seropositive 
heart donors are at greatest risk for reactivation post-
transplant. Reactivation disease in other seronegative 
organ transplant recipients can result in a nonspecifi c 
syndrome of multiorgan failure post-transplant that is 
often fatal if not recognized.
Latent bacterial infection with syphilis can be 
assessed using Rapid plasma reagin testing. 
Positive tests can be further confi rmed with 
specifi c treponemal assays and treated. While 
latent infection with Mycobacterium tuberculosis 
can be detected using Purifi ed protein derivative 
skin testing or interferon-gamma release assays for 
Mycobacterium tuberculosis. False negative results 
may occur in patients with organ failure as little is 
known about the effi cacy of such testing in patients 
who may be immunocompromised as a result of 
pre-transplant organ dysfunction. Patients who test 
positive for latent tuberculosis should be evaluated 
clinically and radiologically for active disease 
and can be treated for latent tuberculosis where 
indicated.
Further to these tests all transplant candidates should 
also be tested for active infection with bacterial 
pathogens as clinically indicated. Active infections 
should be fully treated prior to transplant whenever 
possible. A thorough assessment of potential 
recipients prior to organ implantation will improve 
graft and patient survival, lower costs, and reduce 
infectious complications post-transplant.
Signifi cance of Panel Reactive Antibody 
Testing in Renal Transplant Patients
Maheen Hassan, Sheeba Parveen, Abdul Jabbar and 
Tariq Moatter
Molecular Pathology 
Introduction
The immune system makes abundance of proteins 
called antibodies. When an antibody recognizes the 
foreign proteins in case of infectious agent, organ 
transplant, blood transfusion and/or as a result of 
pregnancy, it recruits other proteins and cells to fi ght 
these foreign bodies off.
 
In case of an organ transplant patient, when one of 
the organs of the patient has failed to work due to 
illness or injury, antibody screening is essential. 
Before organ transplant, doctors must match if the 
recipient has pre-existing panel of antibodies that 
may react against donor’s organ in order to reduce 
the chances of graft rejection.
Panel Reactive Antibody (PRA) is an immunological 
test routinely performed on the blood of people 
awaiting organ transplantation. The PRA score 
is expressed as a percentage between 0 per cent 
and 99 per cent that represents the likelihood of 
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be given a more advanced regimen of anti-rejection 
medications.
Principle of the Assay
Panel Reactive antibody testing utilizes a panel of 
color-coded beads, which are coated with purifi ed 
HLA antigens. Test serum is fi rst incubated with 
beads, any HLA antibodies present in the test serum 
bind to the antigens and then are labeled with 
R-Phycoerythrin (PE)-conjugated Goat anti-human 
IgG. The fl ow analyzer detects the fl uorescent 
emission of PE from each bead, allowing almost 
real-time data acquisition.
Conclusion
Till date, PRA is the sole established quantitative 
indicator of pre-transplantation immunologic 
responsiveness. The exact incidence of humoral 
alloimmune responses after kidney transplantation 
is still uncertain, as routinely post-transplantation 
monitoring of antibodies is not performed. An 
allograft is the most important cause for development 
of antibodies, but transfusions, infections, and 
pregnancy can also stimulate antibody formation; the 
degree of sensitization is stronger and more prolonged 
when different causes act together in the same person.
the recipient’s blood having an antibody against a 
particular donor. It represents the proportion of the 
population to which the person being tested will 
react via pre-existing antibodies. These antibodies 
target the Human Leukocyte Antigen (HLA), a 
protein found on most cells of the body. 
A high PRA usually means that the individual is 
primed to react immunologically against a large 
proportion of the population. Individuals with a 
high PRA are often termed “sensitized”, which 
indicates that they have been exposed to “foreign” 
(or “non-self”) proteins in the past and have 
developed antibodies to them. Transplanting organs 
into recipients who are “sensitized” to the organs 
signifi cantly increases the risk of rejection, resulting 
in higher immunosuppressant requirement and 
shorter transplant survival. People with high PRA 
therefore spend longer waiting for an organ to which 
they have no pre-existing antibodies.
Anti HLA antibodies are usually referred to as panel 
reactive antibodies (PRA) test that sometimes as 
referred to as percent reactive antibody, since the 
result is expressed as percentage.
Utility of the Assay
PRA is a very useful marker in renal transplantation. 
Monitoring panel reactive antibody levels is 
important with kidney transplant candidates. High 
PRA levels mean that doctors have more diffi culty 
locating a matching donor, which can present a 
problem if an immediate transplant is necessary. 
This means that patients with a higher PRA count 
may have to wait much longer for a matching donor 
kidney. Patients with elevated PRA levels are also 
more likely to experience organ rejection and must 
Figure 1. Principle of Panel reactive Antibody Testing
Source: www.szabo-scandic.com/uploads/media/OLI_ProductCata-
log2013-14_web.pdf
Importance of Monitoring Cytomegalovirus 
(CMV) and BKV (Polyomavirus) Infection in 
Renal Transplant Patients
Dr Mahesh Kumar                                                                                                                         
Molecular Pathology 
Kidney transplantation is indicated in patients 
with end stage renal disease, patients who have 
estimated  renal function <20 per cent of normal on 
two sequential determinant  or dialysis dependent 
or signifi cant signs and symptoms of uremia such as 
nausea, loss of appetite, insomnia or chronic fatigue 
Detection by R-Phycoerythrin Conjugated Antibody
1 2 3 4 5Add sample. Wash. Add R-PE
conjugated Anti-IgG.
Wash. Read.
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and ischemia-reperfusion injury stimulate viral 
replication and alterations in the expression of virus 
specifi c cell-surface receptors. The host response 
is also less effective because of the mismatch in 
major histocompatibility antigens between the organ 
donor and host, which reduces the effi cacy of direct 
pathway antiviral cellular immune responses. These 
factors render the allograft susceptible to invasive 
viral infection.
Clinical Value of Viral Load Screening and 
Monitoring
CMV
Cytomegalovirus is the “classic” transplant 
associated viral infection. It causes fever, malaise, 
leucopenia, thrombocytopenia, and allograft 
dysfunction.  Even asymptomatic infection with 
CMV is associated with renal allograft dysfunction, 
mortality, and graft loss, despite early detection and 
treatment of asymptomatic infections. Poor outcomes 
are associated with poor HLA matching and may 
refl ect increased immunogenicity, infl ammatory 
response, or failure to clear CMV.  Figure 1 showing 
CMV virion structure.
Figure 1. The HCMV virion.
The cartoon represents (not to scale) an average HCMV infectious viral 
particle. Abundant  tegument proteins are listed. The large shapes on 
the surface of the virion represent various virally encoded membrane 
glycoproteins.
Source: mmbr.asm.org/content/72/2/249/F1.large.jpg
 
BKV
The BK virus, named after the initials of the patient 
in which it was fi rst isolated is the most recently 
recognized viral pathogen affecting renal transplant 
recipients. It was originally reported in 1971. Primary 
infection usually occurs early in the childhood, at a 
median age of fi ve years, and is characterized by low 
upper respiratory tract morbidity or is asymptomatic. 
Following primary infection, BKV remain latent in 
or acid-base or electrolyte irregularities unresponsive 
to oral treatment. Viral infections i.e. CMV and BKV 
are major problem in these allograft recipients, most 
commonly one - six months after transplantation, 
results from reactivation of “latent” viral infection 
in the host or from the graft. Therefore, monitoring 
for reactivation of these viral infections should be 
routine.
Viral Latency and Reactivation
The nature of viral latency varies with the specifi c 
virus, the tissue infected, and the nature of the 
host immune response. Some latent viruses 
are metabolically inactive, whereas others are 
constantly replicating at low levels determined by 
the effectiveness of the host’s immune response. 
Multiple factors contribute to viral activation after 
transplantation, including immune suppression 
(especially reduction of cytotoxic immunity), graft 
rejection and therapy, infl ammation (cytokines), 
and tissue injury.  Cellular pathways activated after 
transplantation are involved in the control of viral 
replication, including nuclear factor KB, IKB, and 
JAK-STAT (the Janus family of protein tyrosine 
kinases [JAKS] and signal transducers and activators 
of transcription [STAT]proteins) . Treatment of 
rejection can also result in a signifi cant release of 
proinfl ammatory cytokines, including TNF-alpha 
and IL-1B, which may increase viral replication. 
Viral latency may be interrupted periodically, 
leading to reactivation and spread of infectious virus 
with recurrent disease. For CMV, viral genomes 
can be found in CD14+ monocytes and CD34+ 
progenitor cells, but the primary reservoir for latent 
cytomegalovirus and the mechanisms by which 
latent CMV infection is maintained are unknown. 
Subclinical activation of CMV is common.  CMV 
reactivation has been extensively studied. Allogeneic 
immune responses and fever (via TNF alpha) have 
been shown in vitro to up-regulate both CMV 
promoter activity and viral replication. Immune 
suppression is not essential for the reactivation 
of latent CMV but serves to perpetuate such 
infections once activated. For other viruses (e.g. 
BK polyomavirus), specifi c types of tissue damage 
(warm ischemia, reperfusion injury, but not cold 
ischemia) may precipitate viral activation. Warm 
ischemia and reperfusion have been linked to an 
infl ammatory state in grafts (via activation of TNF-
alpha, nuclear factorKB, neutrophil infi ltration, 
and nitric oxide synthesis), tubular-cell injury, and 
enhanced expression of cell-surface molecules. 
These changes contribute to viral activation. 
Thus, immune injury, infl ammatory cytokines, 
pp65
pUL47
pUL48
pp150
pp28
pp71
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different sites, including the Reno urinary tract, as the 
epidemiologically most relevant latency site, B cells, 
brain, spleen, and probably other organs. Periodical 
reactivation may occur in both immunocompetent 
individuals (in 0 per cent up to 62 per cent) and 
immunocompromised patients and is evidenced 
by asymptomatic viruria.  In the current era of 
immunosuppression, BK virus causes nephropathy 
in up to eight per cent of recipients, and frequently 
results in allograft loss or permanent dysfunction. It 
presents as an asymptomatic gradual rise in creatinine 
with a tubulointerstitial nephritis that mimics rejection 
on biopsy and produces a treatment dilemma. Viral 
replication begins early after transplantation and 
progresses through detectable stages - viruria, then 
viremia, then nephropathy. Figure 2 showing BK virus 
genome structure.
Diagnosis 
Molecular techniques including PCR are monitoring 
tests of choice. Qualitative CMV PCR detects only 
presence/absence of viral DNA and is useful in 
systemic CMV infection in immunocompromised 
patients, antenatal diagnosis of congenital CMV 
infection, CMV retinitis and encephalomyelitis 
whereas quantitative CMV detects “viral load” 
which identifi es both virologic response (guiding 
therapy duration) as well as possible presence of 
antiviral resistance. Molecular Pathology department 
Aga Khan hospital is performing qualitative and 
quantitative CMV and quantitative BK virus PCR.
Figure 2. Schematic representation of the gene organization in the BK 
virus (BKV) genome. The double circle represents the double stranded 
DNA genomes. The genome is divided into three  regions. The early 
region encodes three regulatory proteins (Agt, AgT, T’). The late region 
specifi es four structural proteins and  agnoprotein (VP1, VP2, VP3, 
VPx). The non-coding control region contains the elements for the 
control of viral DNA  replication ( ori) and viral gene expression The 
arrows indicate the positive and negative strands according to the 
direction of viral transcription    
Source: Mischitelli et al. Virology Journal 2008 5:38   
Qualitative CMV PCR
Principle: DNA is extracted from blood followed by 
PCR amplifi cation of conserve region of the DNA 
polymerase of CMV by real time PCR. Human 
apoprotein gene is also amplifi ed simultaneously and 
serves as internal control. Interpretation of the assay 
is based on the strength of fl uorescence signals.
Quantitative CMV PCR
Principle: DNA extraction from plasma is followed 
by PCR amplifi cation performed in real time PCR 
instrument. The PCR primers and probes target genes 
within the CMV genome and provide viral load in 
IU/ml. Lower detection limit of the assay is 30 IU/
ml. PCR results are shown in Figure 3.
Quantitative BKV
Principle:  DNA is extracted from serum or urine 
sample followed by amplifi cation by real time PCR. 
The PCR primers and probes target genes within the 
BKV genome and provide viral load in IU/ml. PCR 
results are shown in Figure 4.
Conclusion 
Both viruses are opportunists in the setting of 
transplantation, with potential effects, the clinical 
Figure 3.  Two positive (active infection and latent infection) clinical 
samples was tested . All positive samples were amplifi ed and the cycle 
threshold show the difference between an active infection and a latent 
infection
Figure 4. Result interpretation: Quantifi cation Standards (black), a 
positive (red) and a negative sample (blue) displayed in the Amplifi cation 
Plot (A) and Standard Curve analysis (B).
Active Infection
Latent Infection
Negative CTRL
A1
A2
F4
F5
H6
H9
Threshold
Cycle Ct
A1
A2
F4
F5
H6
H9
32.5
33.1
40.2
40.2
N/A
N/A
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problems currently associated with either virus 
are fundamentally different. CMV can affect 
any organ system, with substantial morbidity 
and mortality, all of which can be essentially 
controlled by effective antivirals. BKV on 
the other hand causes severe pathologies in 
the Reno urinary tract in a limited number of 
kidney transplant recipients. Access to invasive 
procedures and biopsy workup is required for 
definitive diagnosis of CMV and BKV disease. 
However, for both agents, the most relevant 
diagnostic study in the clinical setting is early 
detection and quantification of virus replication 
in blood. Assays quantifying virus-specific 
cellular immune responses in real-time are 
important new avenues to be explored to better 
predict risk of replication and disease and to 
optimize clinical management.
Dr Lena Jafri
Chemical Pathology
The Committee on Reference Intervals and 
Decision Limits (C-RIDL), IFCC Meeting related 
to ‘Global Multicenter Study on Reference Values’ 
was held at the Fukuoka International Convention 
Center, Japan on 24th and 25th November 2014. 
It was chaired by Professor Kiyoshi Ichihara, 
Professor Department of Clinical Laboratory 
Science, Yamaguchi University Graduate School 
of Medicine, Chair, C-RIDL, IFCC and the 
coordinator of the Global Multicenter Study on 
Reference Values. After a welcome to participants 
and a short tour-de-table, Prof. Ichihara described 
background and objectives of the meeting. He 
updated the group that there were nineteen 
countries from 5 continents collaborating in 
this global study; collaborating countries were 
Turkey, Japan, China, India, Philippines, US, UK, 
Argentina, Saudi Arabia, Kenya , Nigeria, Russia, 
Nepal, Bangladesh, Pakistan, Denmark, Egypt and 
Malaysia. He displayed the current status of each 
country, the number of analytes proposed, country 
codes, sample size, test panels and fi nancial support 
of each region. 
It was well attended by, principal investigators 
and co-investigators of the global C-RIDL study 
from various countries; India, Saudi Arabia, China, 
Russia, Nepal, South Africa, Philippines, Pakistan. 
Bangladesh, Egypt and Malaysia. The meeting 
continued as each country representative gave a 
quick update and progress report of their study. 
Representatives invited from Pakistan were Dr 
Meeting Report: Committee on Reference   
Intervals and Decision Limits (C-RIDL), 
IFCC Meeting, Symposium and Workshop
Lena Jafri, from Section of Chemical Pathology, 
Department of Pathology & Microbiology AKUH 
and Prof. Dr Brig. Dilshad, from Armed Forces 
Institute Rawalpindi. The Aga Khan University 
is one of the collaborators of this study and there 
is an additional interest in exploring infl uence of 
ethnicity on reference intervals within Pakistan. 
This is a unique opportunity for AKUH since no 
reference interval is available which has been 
derived from the local population. AKUH with its 
countrywide extensive network is well equipped to 
take on a study of this magnitude.
Prof. Ichihara explained to the members the 
difference between primary and secondary 
exclusion criteria. He clarifi ed to the members 
that to reveal a comprehensive picture of 
reference intervals, C-RIDL is coordinating this 
multicenter RI study with recruitment of a suffi cient 
number of individuals to ensure traceability and 
harmonization of the test results. This was followed 
by suggestions and tips for recording questionnaire 
and use of codes for drugs while entering data 
was advised. The morning meeting was followed 
by a Symposium “IFCC Global multicenter study 
on reference values: major fi ndings and their 
implications” in the afternoon. It was coordinated 
by Prof. Ichihara and Prof. Rajiv Erasmus from 
Stellenbosch University, South Africa. This session 
had several speakers who discussed fi ndings from 
their respective population. The study collaborators 
from China, Saudi Arabia, India and South Africa 
presented their results of their regions using the 
same IFCC-CRIDL protocol. This was followed by 
an intense question answer session.
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On the 25th Nov C-RIDL meeting continued and all 
the members gathered at the Fukuoka International 
Convention Center again. Extensive discussion on 
statistical tools used like parametric versus non-
parametric, bootstrap method for smoothing the 
reference intervals and prediction of 90% confi dence 
interval of reference intervals limits was done. This 
meeting was followed by a workshop “Hands-on: 
Statistical methods for the reference interval study”. 
The new and latest software ‘RI-Master’ made by 
Reo Kawano and Prof. Ichihara was introduced 
to the group. The software was provided to all the 
participants and a hands-on training session was 
given. This session enabled the participants to get to 
know the statistical software, removing curiosity and 
perhaps some trepidation.
Early morning on the 26th November the group 
set off for an excursion to Kumamoto where the 
witnessed volcanic unrest of Mount ‘Aso’, hot 
springs and the four hundred year old Kumamoto 
Castle. This trip provided us an opportunity to 
interact and share ideas in an informal setting. The 
event ended with a traditional multi-course Japanese 
style farewell dinner, Kaiseki ( ) in a quiet 
tranquil environment.  
Investigators and co-investigators from various regions of the world at the ‘Committee on Reference Intervals and Decision Limits 
(C-RIDL), IFCC’ Meeting
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1.
2.
3.
4.
5.
6.
7.
Valproic 
Acid
Tegretol
Phenytoin 
Phenobarbital
 
Gentamicin
Vancomycin
Amikacin
Trough (predose)
Trough (predose)
Trough (predose)
Trough (predose)
Peak testing (after 2-4 hours post 
dose) Trough (predose)
Trough Vancomycin concentrations 
are the most accurate and 
practical method to guide 
Vancomycin dosing. Serum trough 
concentrations should be obtained 
prior to the fourth or fi fth dose.
Peak testing (after 2-4 hours post 
dose) Trough (predose)
50 - 100 μg/ml
4-12 μg/ml
10-20ug/ml
10-40ug/ml
Peak:
Less severe infection 5-8 ug/ml
Severe infection 8-10  ug/ml
Trough:
Less severe infection<1.0ug/ml
Moderate infection<2.0ug/ml
Severe infection<4.0ug/ml
Toxic:
Trough > 2.0 ug/ml
Peak > 10.0 ug/ml
Therapeutic concentration >10 ug/ml
Trough  15-20 ug/ml
Trough 5-10 ug/ml
Peak 20-25  ug/ml
Toxic:
Trough > 10 ug/ml
Peak > 35 ug/ml
Same day
Same day
Performed from 
Monday to Friday and 
reported same day
Performed  from 
Monday to Friday and 
reported same day
Same day
Same day
Same day
Details Of Therapeutic Drug Monitoring
Hafsa Majid, Chemical Pathology
Drug ReportingTime of Sample Collection Therapeutic RangesS. No
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8.
9
10.
11.
12.
13.
14.
Cyclosporin 
Cyclosporin 
C2 
Monitoring
Tacrolimus
Methotrexate 
Lithium
Theophylline
Digoxin
Trough (predose)
Peak testing (after 2-4 hours post 
dose)
Trough (predose)
Trough (predose) Collect sample 
after 72 hours of therapy
Trough (Predose or after 12 hours 
post dose)
Peak testing (after 2-4 hours post 
dose) Trough (predose)
Peak tissue concentration (after 8 
hours post dose)
Trough (predose)
Post renal transplants:
Upto 2 months 200-300 ng/ml
3 months 200 ng/ml
4-12 months 80-180 ng/ml
Post liver transplants:
≤ 1 month 350-450 ng/ml
2-6 months 250-350 ng/ml
>6 months 170-240 ng/ml
Post cardiac transplants:
<6 weeks 300-420 ng/ml
6-12 weeks 180-300 ng/ml
>12 weeks 120-180 ng/ml
Post renal transplant:
Upto 1 month 1700 ng/ml
2 months 1500 ng/ml
3-4 months 1200 ng/ml
5-6 months 1000 ng/ml
7-12 months 800 ng/ml
5-20 ng/ml
Non-toxic concentration <0.1 umol/l
Therapeutic Range: 0.6 - 1.2mmol/l
Toxic: >2.0mmol/l
Therapeutic Range 10-20ug/ml
Therapeutic Range 0.9-2.0ng/ml
Toxic >2.0ng/ml
Special instruction: Mention drug dosing frequency, route and sample is trough or peak. Mention STAT on the request 
slip if results are needed urgently. 
Performed  from 
Monday to Saturday 
and reported same day
Results of inpatients 
undergoing transplant 
are reported within 4 
hours after receiving 
specimen.
Performed  from 
Monday to Saturday 
and reported same day
Results of inpatients
 undergoing transplant 
are reported within 4 
hours after receiving 
specimen.
Performed on 
Wednesday and 
reported next day 
Results of inpatients 
undergoing transplant 
are reported within 4 
hours after receiving 
specimen.
Same day
Same day
Same day
Same day
Drug ReportingTime of Sample Collection Therapeutic RangesS. No
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Tests
Price
Tests
Price
Tests
Price
CBC
700
        
Serum
 Sodium
410
          
SGPT (ALT)
380
        
U
rine D/R
380
        
Serum
 Chloride
410
          
Hepatits B Surface Antigen 
1,300
     
Stool D/R
390
        
Serum
 Potassium
410
          
Hepatits B Surface Antibody
1,600
     
Fasting Gulcose
370
        
Serum
 Bicarbonate
410
          
Anti HCV
2,400
     
Fasting Cholestrol
600
        
Blood U
rea N
itrogen
600
          
Total
5,680
     
Serum
 Creatinine
660
        
Serum
 Creatinine
660
          
Discount 
1,130
     
Liver Function Test
1,450
     
U
rine D/R
380
          
Package Price after discount (rounded to 10)
4,550
     
Total
4,550
     
Anion Gap (calculated value)
60
            
Discount 
910
        
Total
3,340
       
Package Price after discount (rounded to 10)
3,640
     
Discount 
660
          
Tests
Price
Package Price after discount (rounded to 10)
2,680
       
Serum
 Iron
840
        
TIBC
780
        
Tests
Price
Serum
 Ferritin
1,750
     
CBC
700
        
Tests
Price
Total
3,370
     
U
rine D/R
380
        
Serum
 Sodium
410
          
Discount 
670
        
Stool D/R
390
        
Serum
 Chloride
410
          
Package Price after discount (rounded to 10)
2,700
     
Fasting Gulcose
370
        
M
icro Album
in
1,050
       
Serum
 Creatinine
660
        
Serum
 Potassium
410
          
Liver Function Test
1,450
     
Serum
 Bicarbonate
410
          
Tests
Price
Lipid Profile
2,250
     
Blood U
rea N
itrogen
600
          
Fasting Gulcose
370
        
HepBs Ag
1,300
     
Creatinine Clearance (m
l/m
in)
1,600
       
HsCRP
1,600
     
HepC AB
2,400
     
U
rine D/R
380
          
Lipid Profile
2,250
     
Total
9,900
     
Anion Gap (calculated value)
60
            
Hom
ocysteine
2,400
     
Discount 
1,980
     
Serum
 Calcium
600
          
Total
6,620
     
Package Price after discount (rounded to 10)
7,920
     
Serum
 Phosphorous
620
          
Discount 
1,320
     
Serum
 Parathroid Horm
one
2,650
       
Package Price after discount (rounded to 10)
5,300
     
Serum
 U
ric Acid
650
          
Album
in / Creatinine Ratio Per 24 hours
50
            
Tests
Price
Total
9,900
       
Tests
Price
Vitam
in B12
2,000
     
Discount 
1,980
       
CBC
700
        
RBC Folate
1,990
     
Package Price after discount (rounded to 10)
7,920
       
Rscreen
1,200
     
Total
3,990
     
U
rine D/R
380
        
Discount
790
        
HBSAG
1,300
     
Package Price after discount (rounded to 10)
3,200
     
HCV
2,400
     
RU
BIGG
1,750
     
RU
BIGM
2,150
     
Tests
Price
Anti-TPO
900
        
Calcium
 
600
        
Tests
Price
Total
10,780
  
Album
in
400
        
Calcium
 
600
          
Discount 
1,610
     
Corrected Total Calcium
 (calculated value)
60
          
Album
in
400
          
Package Price after discount (rounded to 10)
9,170
     
Phosphorus
620
        
Corrected Total Calcium
 (calculated value)
60
            
M
agnesium
1,040
     
Phosphorus
620
          
Creatinine
660
        
25 O
H VIT D
3,500
       
Tests
Price
PTH
2,650
     
PTH
2,650
       
Reticulocyte Count
500
        
ALP
500
        
ALP
500
          
LDH
600
        
25 O
H VIT D
3,500
     
N
TX
6,100
       
Direct Coom
bs Test
660
        
Total
10,030
  
Total
14,430
    
Total
1,760
     
Discount 
2,000
     
Discount 
2,880
       
Discount 
350
        
Package Price after discount (rounded to 10)
8,030
     
Package Price after discount (rounded to 10)
11,550
    
Package Price after discount (rounded to 10)
1,410
     
 Discount On Special Packages Year 2015
H
epatitis Screening Package
Package Code : HEPSP
M
icrocytic Package
Package Code : 
ANEMP
C
ardiac R
isk Package
TT
H
E
 A
G
A
 K
H
A
N
 U
N
IV
E
R
S
IT
Y
 H
O
S
P
IT
A
L,
Extended H
ealth Screening Package
Package Code: EHSP
B
one H
ealth Screening Package
M
acrocytic Package
Package Code: MACP
Package Code : OSTPP
O
steoporosis Package
Package Code: BHSP
CC
LIN
IC
A
L LA
B
O
R
A
T
O
R
IE
S
 - K
A
R
A
C
H
I
H
ealth Screening Package
Package Code : HSP
Package Code : HEMANE
Package Code : RFTP
Extended R
enal Function Tests Package
Package Code : ERFTP
R
enal Function Test Package
Package Code : CARP
A
ntenatal Package
H
em
olytic Panel
Package Code :ANTP
hospitals.aku.edu/Karachi/clinical-laboratories
